{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T22:12:46Z","timestamp":1794003166168,"version":"4.8.0"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,2,19]],"date-time":"2024-02-19T00:00:00Z","timestamp":1708300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,2,19]],"date-time":"2024-02-19T00:00:00Z","timestamp":1708300800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Lung adenocarcinoma (LUAD) is a prevalent form of non-small cell lung cancer with a rising incidence in recent years. Understanding the mutation characteristics of LUAD is crucial for effective treatment and prediction of this disease. Among the various mutations observed in LUAD, KRAS mutations are particularly common. Different subtypes of KRAS mutations can activate the Ras signaling pathway to varying degrees, potentially influencing the pathogenesis and prognosis of LUAD. This study aims to investigate the relationship between different KRAS mutation subtypes and the pathogenesis and prognosis of LUAD. A total of 63 clinical samples of LUAD were collected for this study. The samples were analyzed using targeted gene sequencing panels to obtain sequencing data. To complement the dataset, additional clinical and sequencing data were obtained from TCGA and MSK. The analysis revealed significantly higher Ki67 immunohistochemical scores in patients with missense mutations compared to controls. Moreover, the expression level of KRAS was found to be significantly correlated with Ki67 expression. Enrichment analysis indicated that KRAS missense mutations activated the SWEET_LUNG_CANCER_KRAS_DN and CREIGHTON_ENDOCRINE_THERAPY_RESISTANCE_2 pathways. Additionally, patients with KRAS missense mutations and high Ki67 IHC scores exhibited significantly higher tumor mutational burden levels compared to other groups, which suggests they are more likely to be responsive to ICIs. Based on the data from MSK and TCGA, it was observed that patients with KRAS missense mutations had shorter survival compared to controls, and Ki67 expression level could more accurately predict patient prognosis. In conclusion, when utilizing KRAS mutations as biomarkers for the treatment and prediction of LUAD, it is important to consider the specific KRAS mutant subtypes and Ki67 expression levels. These findings contribute to a better understanding of LUAD and have implications for personalized therapeutic approaches in the management of this disease.<\/jats:p>","DOI":"10.1038\/s41598-023-48307-x","type":"journal-article","created":{"date-parts":[[2024,2,19]],"date-time":"2024-02-19T12:03:32Z","timestamp":1708344212000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Effects of different KRAS mutants and Ki67 expression on diagnosis and prognosis in lung adenocarcinoma"],"prefix":"10.1038","volume":"14","author":[{"given":"Jun","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liwen","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaowei","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baisheng","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiongwei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bing","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,2,19]]},"reference":[{"issue":"11 Pt 1","key":"48307_CR1","doi-asserted-by":"publisher","first-page":"3344","DOI":"10.1158\/1078-0432.CCR-05-2336","volume":"12","author":"L Guo","year":"2006","unstructured":"Guo, L. et al. Constructing molecular classifiers for the accurate prognosis of lung adenocarcinoma. Clin. Cancer Res. 12(11 Pt 1), 3344\u20133354 (2006).","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"48307_CR2","doi-asserted-by":"publisher","first-page":"235","DOI":"10.3892\/ijmm.2017.2989","volume":"40","author":"X Chen","year":"2017","unstructured":"Chen, X. et al. The Cdc2\/Cdk1 inhibitor, purvalanol A, enhances the cytotoxic effects of taxol through Op18\/stathmin in non-small cell lung cancer cells in vitro. Int. J. Mol. Med. 40(1), 235\u2013242 (2017).","journal-title":"Int. J. Mol. Med."},{"key":"48307_CR3","doi-asserted-by":"publisher","first-page":"1007831","DOI":"10.3389\/fmicb.2022.1007831","volume":"13","author":"X Yuan","year":"2022","unstructured":"Yuan, X. et al. Bacterial biomarkers capable of identifying recurrence or metastasis carry disease severity information for lung cancer. Front. Microbiol. 13, 1007831 (2022).","journal-title":"Front. Microbiol."},{"issue":"7","key":"48307_CR4","doi-asserted-by":"publisher","first-page":"1855","DOI":"10.3390\/jcm11071855","volume":"11","author":"R Ushio","year":"2022","unstructured":"Ushio, R., Murakami, S. & Saito, H. Predictive markers for immune checkpoint inhibitors in non-small cell lung cancer. J. Clin. Med. 11(7), 1855 (2022).","journal-title":"J. Clin. Med."},{"issue":"1","key":"48307_CR5","first-page":"45","volume":"25","author":"KC Thandra","year":"2021","unstructured":"Thandra, K. C., Barsouk, A., Saginala, K., Aluru, J. S. & Barsouk, A. Epidemiology of lung cancer. Contemp. Oncol. (Pozn) 25(1), 45\u201352 (2021).","journal-title":"Contemp. Oncol. (Pozn)"},{"key":"48307_CR6","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.omtm.2020.05.020","volume":"18","author":"Z Song","year":"2020","unstructured":"Song, Z. et al. Evaluating the potential of T cell receptor repertoires in predicting the prognosis of resectable non-small cell lung cancers. Mol. Ther. Methods Clin. Dev. 18, 73\u201383 (2020).","journal-title":"Mol. Ther. Methods Clin. Dev."},{"issue":"1","key":"48307_CR7","first-page":"501","volume":"41","author":"Y Zhao","year":"2019","unstructured":"Zhao, Y. et al. In vitro neutralization of autocrine IL10 affects Op18\/stathmin signaling in nonsmall cell lung cancer cells. Oncol. Rep. 41(1), 501\u2013511 (2019).","journal-title":"Oncol. Rep."},{"issue":"3","key":"48307_CR8","first-page":"2051","volume":"41","author":"S Chen","year":"2019","unstructured":"Chen, S. et al. Introduction of exogenous wildtype p53 mediates the regulation of oncoprotein 18\/stathmin signaling via nuclear factorkappaB in nonsmall cell lung cancer NCIH1299 cells. Oncol. Rep. 41(3), 2051\u20132059 (2019).","journal-title":"Oncol. Rep."},{"key":"48307_CR9","doi-asserted-by":"publisher","first-page":"619330","DOI":"10.3389\/fcell.2021.619330","volume":"9","author":"H Liu","year":"2021","unstructured":"Liu, H. et al. Evaluating DNA methylation, gene expression, somatic mutation, and their combinations in inferring tumor tissue-of-origin. Front. Cell. Dev. Biol. 9, 619330 (2021).","journal-title":"Front. Cell. Dev. Biol."},{"key":"48307_CR10","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3389\/fbioe.2020.00394","volume":"8","author":"B He","year":"2020","unstructured":"He, B. et al. TOOme: A novel computational framework to infer cancer tissue-of-origin by integrating both gene mutation and expression. Front. Bioeng. Biotechnol. 8, 394 (2020).","journal-title":"Front. Bioeng. Biotechnol."},{"key":"48307_CR11","volume-title":"Thoracic Tumours","author":"WHO Classification of Tumours Editorial Board","year":"2021","unstructured":"WHO Classification of Tumours Editorial Board. Thoracic Tumours Vol. 5 (International Agency for Research on Cancer, 2021)."},{"issue":"1","key":"48307_CR12","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1007\/s12022-023-09755-3","volume":"34","author":"S La Rosa","year":"2023","unstructured":"La Rosa, S. Diagnostic, prognostic, and predictive role of Ki67 proliferative index in neuroendocrine and endocrine neoplasms: Past, present, and future. Endocr. Pathol. 34(1), 79\u201397 (2023).","journal-title":"Endocr. Pathol."},{"key":"48307_CR13","doi-asserted-by":"publisher","first-page":"7761589","DOI":"10.1155\/2022\/7761589","volume":"2022","author":"W Yao","year":"2022","unstructured":"Yao, W. et al. Noninvasive method for predicting the expression of Ki67 and prognosis in non-small-cell lung cancer patients: Radiomics. J. Healthc. Eng. 2022, 7761589 (2022).","journal-title":"J. Healthc. Eng."},{"issue":"3","key":"48307_CR14","first-page":"66","volume":"48","author":"IN Soomro","year":"1998","unstructured":"Soomro, I. N., Holmes, J. & Whimster, W. F. Predicting prognosis in lung cancer: Use of proliferation marker, Ki67 monoclonal antibody. JPMA J. Pak. Med. Assoc. 48(3), 66\u201369 (1998).","journal-title":"JPMA J. Pak. Med. Assoc."},{"issue":"5","key":"48307_CR15","first-page":"100277","volume":"3","author":"X Shi","year":"2022","unstructured":"Shi, X., Young, S., Cai, K., Yang, J. & Morahan, G. Cancer susceptibility genes: Update and systematic perspectives. Innovation (Camb) 3(5), 100277 (2022).","journal-title":"Innovation (Camb)"},{"key":"48307_CR16","unstructured":"World Health Organization. Regional Office for South-East A: Integrated regional action plan for viral hepatitis, HIV and sexually transmitted infections in South-East Asia; 2022\u20132026. New Delhi: World Health Organization. Regional Office for South-East Asia (2022)."},{"key":"48307_CR17","first-page":"8","volume":"2","author":"P Westcott","year":"2013","unstructured":"Westcott, P. & To, M. The genetics and biology of KRAS in lung cancer. Chin. J. Cancer 2, 8 (2013).","journal-title":"Chin. J. Cancer"},{"issue":"2","key":"48307_CR18","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1513\/pats.200809-107LC","volume":"6","author":"GJ Riely","year":"2009","unstructured":"Riely, G. J., Marks, J. & Pao, W. KRAS mutations in non-small cell lung cancer. Proc. Am. Thorac. Soc. 6(2), 201\u2013205 (2009).","journal-title":"Proc. Am. Thorac. Soc."},{"issue":"3","key":"48307_CR19","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.cllc.2012.09.007","volume":"14","author":"N Karachaliou","year":"2013","unstructured":"Karachaliou, N. et al. KRAS mutations in lung cancer. Clin. Lung Cancer 14(3), 205\u2013214 (2013).","journal-title":"Clin. Lung Cancer"},{"issue":"7609","key":"48307_CR20","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1038\/nature18600","volume":"534","author":"E Manchado","year":"2016","unstructured":"Manchado, E. et al. A combinatorial strategy for treating KRAS-mutant lung cancer. Nature 534(7609), 647\u2013651 (2016).","journal-title":"Nature"},{"issue":"4","key":"48307_CR21","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1007\/s10555-020-09903-9","volume":"39","author":"A Ghimessy","year":"2020","unstructured":"Ghimessy, A. et al. Current therapy of KRAS-mutant lung cancer. Cancer Metastasis Rev. 39(4), 1159\u20131177 (2020).","journal-title":"Cancer Metastasis Rev."},{"issue":"4","key":"48307_CR22","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1158\/2159-8290.CD-22-0035","volume":"12","author":"C Johnson","year":"2022","unstructured":"Johnson, C., Burkhart, D. L. & Haigis, K. M. Classification of KRAS-activating mutations and the implications for therapeutic intervention. Cancer Discov. 12(4), 913\u2013923 (2022).","journal-title":"Cancer Discov."},{"key":"48307_CR23","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-018-0076-6","author":"S Li","year":"2018","unstructured":"Li, S., Balmain, A. & Counter, C. M. A model for RAS mutation patterns in cancers: Finding the sweet spot. Nat. Rev. Cancer https:\/\/doi.org\/10.1038\/s41568-018-0076-6 (2018).","journal-title":"Nat. Rev. Cancer"},{"issue":"12","key":"48307_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s12276-018-0191-1","volume":"50","author":"P Darvin","year":"2018","unstructured":"Darvin, P., Toor, S. M., Sasidharan Nair, V. & Elkord, E. Immune checkpoint inhibitors: Recent progress and potential biomarkers. Exp. Mol. Med. 50(12), 1\u201311 (2018).","journal-title":"Exp. Mol. Med."},{"key":"48307_CR25","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1016\/j.ebiom.2019.02.049","volume":"41","author":"H Adderley","year":"2019","unstructured":"Adderley, H., Blackhall, F. H. & Lindsay, C. R. KRAS-mutant non-small cell lung cancer: Converging small molecules and immune checkpoint inhibition. EBioMedicine 41, 711\u2013716 (2019).","journal-title":"EBioMedicine"},{"issue":"1","key":"48307_CR26","first-page":"129","volume":"5","author":"Y Li","year":"2022","unstructured":"Li, Y. et al. Resistance to immune checkpoint inhibitors in KRAS-mutant non-small cell lung cancer. Cancer Drug Resist. 5(1), 129\u2013146 (2022).","journal-title":"Cancer Drug Resist."},{"issue":"8","key":"48307_CR27","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1093\/annonc\/mdz167","volume":"30","author":"J Mazieres","year":"2019","unstructured":"Mazieres, J. et al. Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: Results from the IMMUNOTARGET registry. Ann. Oncol. 30(8), 1321\u20131328 (2019).","journal-title":"Ann. Oncol."},{"issue":"29","key":"48307_CR28","doi-asserted-by":"publisher","first-page":"48248","DOI":"10.18632\/oncotarget.17594","volume":"8","author":"JH Kim","year":"2017","unstructured":"Kim, J. H., Kim, H. S. & Kim, B. J. Prognostic value of KRAS mutation in advanced non-small-cell lung cancer treated with immune checkpoint inhibitors: A meta-analysis and review. Oncotarget 8(29), 48248\u201348252 (2017).","journal-title":"Oncotarget"},{"issue":"12","key":"48307_CR29","doi-asserted-by":"publisher","first-page":"4325","DOI":"10.3390\/ijms21124325","volume":"21","author":"IZ Uras","year":"2020","unstructured":"Uras, I. Z., Moll, H. P. & Casanova, E. Targeting KRAS mutant non-small-cell lung cancer: Past, present and future. Int. J. Mol. Sci. 21(12), 4325 (2020).","journal-title":"Int. J. Mol. Sci."},{"issue":"22","key":"48307_CR30","doi-asserted-by":"publisher","first-page":"7765","DOI":"10.1128\/MCB.00965-07","volume":"27","author":"S Schubbert","year":"2007","unstructured":"Schubbert, S. et al. Biochemical and functional characterization of germ line KRAS mutations. Mol. Cell Biol. 27(22), 7765\u20137770 (2007).","journal-title":"Mol. Cell Biol."},{"issue":"2","key":"48307_CR31","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1097\/CCO.0000000000000051","volume":"26","author":"J Timar","year":"2014","unstructured":"Timar, J. The clinical relevance of KRAS gene mutation in non-small-cell lung cancer. Curr. Opin. Oncol. 26(2), 138\u2013144 (2014).","journal-title":"Curr. Opin. Oncol."},{"issue":"12","key":"48307_CR32","doi-asserted-by":"publisher","first-page":"3295","DOI":"10.1158\/0008-5472.CAN-20-3564","volume":"81","author":"R Li","year":"2021","unstructured":"Li, R. et al. Inhibition of granulocytic myeloid-derived suppressor cells overcomes resistance to immune checkpoint inhibition in LKB1-deficient non-small cell lung cancer. Cancer Res. 81(12), 3295\u20133308 (2021).","journal-title":"Cancer Res."},{"key":"48307_CR33","doi-asserted-by":"publisher","DOI":"10.1093\/bioinformatics\/btac641","author":"K Huang","year":"2022","unstructured":"Huang, K. et al. Predicting colorectal cancer tumor mutational burden from histopathological images and clinical information using multi-modal deep learning. Bioinformatics https:\/\/doi.org\/10.1093\/bioinformatics\/btac641 (2022).","journal-title":"Bioinformatics"},{"issue":"2","key":"48307_CR34","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1038\/s41588-018-0312-8","volume":"51","author":"RM Samstein","year":"2019","unstructured":"Samstein, R. M. et al. Tumor mutational load predicts survival after immunotherapy across multiple cancer types. Nat. Genet. 51(2), 202\u2013206 (2019).","journal-title":"Nat. Genet."},{"issue":"11","key":"48307_CR35","doi-asserted-by":"publisher","first-page":"1418","DOI":"10.1158\/2767-9764.CRC-22-0343","volume":"2","author":"ES Christenson","year":"2022","unstructured":"Christenson, E. S. et al. Cell-free DNA predicts prolonged response to multi-agent chemotherapy in pancreatic ductal adenocarcinoma. Cancer Res. Commun. 2(11), 1418\u20131425 (2022).","journal-title":"Cancer Res. Commun."},{"issue":"10","key":"48307_CR36","doi-asserted-by":"publisher","first-page":"2457","DOI":"10.1158\/0008-5472.CAN-11-2612","volume":"72","author":"IA Prior","year":"2012","unstructured":"Prior, I. A., Lewis, P. D. & Mattos, C. A comprehensive survey of Ras mutations in cancer. Cancer Res. 72(10), 2457\u20132467 (2012).","journal-title":"Cancer Res."},{"key":"48307_CR37","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.728575","author":"W Gu","year":"2021","unstructured":"Gu, W. et al. The Ki-67 proliferation index-related nomogram to predict the response of first-line tyrosine kinase inhibitors or chemotherapy in non-small cell lung cancer patients with epidermal growth factor receptor-mutant status. Front. Med. https:\/\/doi.org\/10.3389\/fmed.2021.728575 (2021).","journal-title":"Front. Med."},{"issue":"10","key":"48307_CR38","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1080\/1744666X.2017.1366315","volume":"13","author":"H Yousefi","year":"2017","unstructured":"Yousefi, H., Yuan, J., Keshavarz-Fathi, M., Murphy, J. F. & Rezaei, N. Immunotherapy of cancers comes of age. Expert Rev. Clin. Immunol. 13(10), 1001\u20131015 (2017).","journal-title":"Expert Rev. Clin. Immunol."},{"issue":"9","key":"48307_CR39","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1007\/s11912-018-0718-6","volume":"20","author":"DJ Palmieri","year":"2018","unstructured":"Palmieri, D. J. & Carlino, M. S. Immune checkpoint inhibitor toxicity. Curr. Oncol. Rep. 20(9), 72 (2018).","journal-title":"Curr. Oncol. Rep."},{"issue":"11","key":"48307_CR40","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1111\/1759-7714.14448","volume":"13","author":"Y Uehara","year":"2022","unstructured":"Uehara, Y., Watanabe, K., Hakozaki, T., Yomota, M. & Hosomi, Y. Efficacy of first-line immune checkpoint inhibitors in patients with advanced NSCLC with KRAS, MET, FGFR, RET, BRAF, and HER2 alterations. Thorac. Cancer 13(11), 1703\u20131711 (2022).","journal-title":"Thorac. Cancer"},{"key":"48307_CR41","doi-asserted-by":"publisher","first-page":"175883592110069","DOI":"10.1177\/17588359211006950","volume":"13","author":"M Gu","year":"2021","unstructured":"Gu, M., Xu, T. & Chang, P. KRAS\/LKB1 and KRAS\/TP53 co-mutations create divergent immune signatures in lung adenocarcinomas. Ther. Adv. Med. Oncol. 13, 17588359211006950 (2021).","journal-title":"Ther. Adv. Med. Oncol."},{"issue":"2","key":"48307_CR42","doi-asserted-by":"publisher","first-page":"bbab581","DOI":"10.1093\/bib\/bbab581","volume":"23","author":"Y Meng","year":"2022","unstructured":"Meng, Y. et al. A weighted bilinear neural collaborative filtering approach for drug repositioning. Brief. Bioinform. 23(2), bbab581 (2022).","journal-title":"Brief. Bioinform."},{"key":"48307_CR43","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1016\/j.omtn.2020.07.003","volume":"21","author":"C Liu","year":"2020","unstructured":"Liu, C. et al. An improved anticancer drug-response prediction based on an ensemble method integrating matrix completion and ridge regression. Mol. Ther. Nucleic Acids 21, 676\u2013686 (2020).","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"48307_CR44","doi-asserted-by":"publisher","first-page":"22811","DOI":"10.1038\/srep22811","volume":"6","author":"X Liu","year":"2016","unstructured":"Liu, X. et al. A systematic study on drug-response associated genes using baseline gene expressions of the cancer cell line encyclopedia. Sci. Rep. 6, 22811 (2016).","journal-title":"Sci. Rep."},{"issue":"4","key":"48307_CR45","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1038\/nrclinonc.2012.22","volume":"9","author":"EH Rubin","year":"2012","unstructured":"Rubin, E. H. & Gilliland, D. G. Drug development and clinical trials\u2013the path to an approved cancer drug. Nat. Rev. Clin. Oncol. 9(4), 215\u2013222 (2012).","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"29","key":"48307_CR46","doi-asserted-by":"publisher","first-page":"eabm8780","DOI":"10.1126\/sciadv.abm8780","volume":"8","author":"EA-O Mugarza","year":"2022","unstructured":"Mugarza, E.A.-O. et al. Therapeutic KRAS(G12C) inhibition drives effective interferon-mediated antitumor immunity in immunogenic lung cancers. Sci. Adv. 8(29), eabm8780 (2022).","journal-title":"Sci. Adv."},{"key":"48307_CR47","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.lungcan.2020.09.004","volume":"149","author":"G Gao","year":"2020","unstructured":"Gao, G. et al. KRAS G12D mutation predicts lower TMB and drives immune suppression in lung adenocarcinoma. Lung Cancer 149, 41\u201345 (2020).","journal-title":"Lung Cancer"},{"key":"48307_CR48","doi-asserted-by":"publisher","first-page":"105697","DOI":"10.1016\/j.compbiomed.2022.105697","volume":"146","author":"J Xu","year":"2022","unstructured":"Xu, J. et al. Evaluating the performance of dropout imputation and clustering methods for single-cell RNA sequencing data. Comput. Biol. Med. 146, 105697 (2022).","journal-title":"Comput. Biol. Med."},{"issue":"10","key":"48307_CR49","doi-asserted-by":"publisher","first-page":"3139","DOI":"10.1093\/bioinformatics\/btaa109","volume":"36","author":"J Xu","year":"2020","unstructured":"Xu, J., Cai, L., Liao, B., Zhu, W. & Yang, J. CMF-Impute: An accurate imputation tool for single-cell RNA-seq data. Bioinformatics 36(10), 3139\u20133147 (2020).","journal-title":"Bioinformatics"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-48307-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-48307-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-48307-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,22]],"date-time":"2024-02-22T16:10:46Z","timestamp":1708618246000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-48307-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,19]]},"references-count":49,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["48307"],"URL":"https:\/\/doi.org\/10.1038\/s41598-023-48307-x","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,19]]},"assertion":[{"value":"14 June 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 November 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 February 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"4085"}}